---
schema_version: "secwatch.filing_event.v1"
accession: "0001387131-23-006973"
form_type: "8-K"
ticker: null
cik: "0000887247"
company_name: "DMK PHARMACEUTICALS Corp"
filed_at: "2023-05-26T23:59:59+00:00"
generated_at: "2026-06-14T13:48:48.820867+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Adamis closes merger with DMK Pharmaceuticals; Ebrahim Versi named CEO and Chair

## Summary
- Merger completed May 25; DMK shareholders received 302,815 Adamis common shares and 1,941.2 Series E Preferred shares.
- Ebrahim Versi appointed CEO and Chair; David Marguglio stepped down as CEO, remains president and COO.
- Series E Preferred convertible at 1,000 common per share; 9.99% beneficial ownership limitation; Nasdaq issuance cap.
- Board changes: Marguglio and Williams resign; Versi and Jannine Versi appointed to board.
- DMK stock options assumed: 231,490 Adamis shares; Dr. Versi holds options for 102,885 shares.

## SEC filing metadata
- accession: 0001387131-23-006973
- form_type: 8-K
- cik: 0000887247
- company_name: DMK PHARMACEUTICALS Corp
- filed_at: 2023-05-26T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 5.02, 2.01, 3.02, 3.03, 5.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/887247/000138713123006973/0001387131-23-006973-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/887247/000138713123006973/admp-8k_052423.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001387131-23-006973
- JSON: https://secwatch.observer/filing/0001387131-23-006973.json
- Plain text: https://secwatch.observer/filing/0001387131-23-006973.txt

## Key facts
- Executive change
  David J. Marguglio resigned as Director at DMK PHARMACEUTICALS Corp.
  - Action: resigned
  - Role: Director
  source text: David J. Marguglio and Richard C. Williams resigned from the Company’s board of directors
  evidence_url: https://www.sec.gov/Archives/edgar/data/887247/000138713123006973/0001387131-23-006973-index.htm
- Executive change
  Jannine Versi was appointed as Director at DMK PHARMACEUTICALS Corp.
  - Action: appointed
  - Role: Director
  source text: Ebrahim Versi and Jannine Versi were appointed to the Board to fill those vacancies
  evidence_url: https://www.sec.gov/Archives/edgar/data/887247/000138713123006973/0001387131-23-006973-index.htm
- Executive change
  Ebrahim (Eboo) Versi was appointed as Chief Executive Officer and Chair of the Board at DMK PHARMACEUTICALS Corp.
  - Action: appointed
  - Role: Chief Executive Officer and Chair of the Board
  source text: Ebrahim (Eboo) Versi, M.D., Ph.D., the co-founder and chief executive officer of DMK, was appointed as the chief executive officer of the Company and as Chair of the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/887247/000138713123006973/0001387131-23-006973-index.htm
- Executive change
  David J. Marguglio was appointed as President and Chief Operating Officer at DMK PHARMACEUTICALS Corp.
  - Action: resigned as chief executive officer and appointed as president and chief operating officer
  - Role: President and Chief Operating Officer
  source text: David J. Marguglio resigned as chief executive officer of Adamis; he continues as president of Adamis and as corporate secretary and was also appointed as chief operating officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/887247/000138713123006973/0001387131-23-006973-index.htm
- Executive change
  Richard C. Williams resigned as Director at DMK PHARMACEUTICALS Corp.
  - Action: resigned
  - Role: Director
  source text: David J. Marguglio and Richard C. Williams resigned from the Company’s board of directors
  evidence_url: https://www.sec.gov/Archives/edgar/data/887247/000138713123006973/0001387131-23-006973-index.htm
- Governance Changes
  DMK PHARMACEUTICALS Corp: Filed Certificate of Designation for Series E Convertible Preferred Stock, designating 15,000 shares as Series E Preferred (effective 2023-05-24).
  - Change: charter amendment
  - Effective: 2023-05-24
  source text: On May 24, 2023, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series E Convertible Preferred Stock (the “Certificate of Designation”) with the Secretary of State of the State of Delaware, designating 15,000 shares out of the authorized but unissued shares of its preferred stock as Series E Preferred
  evidence_url: https://www.sec.gov/Archives/edgar/data/887247/000138713123006973/0001387131-23-006973-index.htm
- M&A Transactions
  DMK PHARMACEUTICALS Corp completed an acquisition involving DMK Pharmaceuticals Corporation (closed 2023-05-25).
  - Action: acquisition
  - Counterparty: DMK Pharmaceuticals Corporation
  - Closing: 2023-05-25
  source text: On May 25, 2023, Adamis Pharmaceuticals Corporation, a Delaware corporation (“Adamis” or the “Company”), completed its merger transaction with DMK Pharmaceuticals Corporation (“DMK”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/887247/000138713123006973/0001387131-23-006973-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.